Drug Chatter -- Tracking biopharma stock chatter

💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…

Profile for Acceleron Pharma Inc. (XLRN)

« Back to company index

XLRN Chatter Timeline

Stock Ticker for XLRN

Most Active Tweeters for XLRN

UserTweets
@newsfilterio 3
@fintel_io 2
@FlashAlert_me 2
@AlertTrade 2
@Biotech2050 2

Recent Tweets for XLRN

SweepCastApp @SweepCastApp
SweepCast observed: $XLRN with Unusual Options Activity Alerted on $140 CALL Expiring: 06-18-2021 worth 237K? |? Se… https://t.co/NvQg0UFFWo
April 19th 2021, 6:04pm
SweepCastApp @SweepCastApp
SweepCast observed: $XLRN with Unusual Options Activity Alerted on $140 CALL Expiring: 06-18-2021 worth 237K? |? Se… https://t.co/5l3XiBMaWi
April 18th 2021, 6:04pm
MarketChmln @MarketChmln
$XLRN option volume was 15X normal on Friday with 2,255 contracts. Call volume was 55% and put volume was 45%. https://t.co/Sh2bIZBdee
April 17th 2021, 5:04pm
WALLSTREETODDS_ @WALLSTREETODDS_
$XLRN Out of the 986 other times XLRN was down 1.9% during a trading day, 56% of the time it traded higher by the… https://t.co/rRH44OmVzd
April 10th 2021, 1:04am
deus_trader @deus_trader
Optimus v4 2021-04-08 13:35 ET. Bought/Opened: $XLRN at $128.71. Acceleron Pharma, Inc (CORP). Win Chance: 71%. Av… https://t.co/Umh8osO0se
April 8th 2021, 5:04pm
AlertTrade @AlertTrade
RT @AlertTrade: REVERSALtoDOWN: $XLRN Acceleron Pharma, Inc https://t.co/vavn4UHszX ? ? TradeIdeas via ? https://t.co/VS8RO1bzXJ
April 8th 2021, 4:04pm
AlertTrade @AlertTrade
REVERSALtoDOWN: $XLRN Acceleron Pharma, Inc https://t.co/vavn4UHszX ? ? TradeIdeas via ? https://t.co/VS8RO1bzXJ
April 8th 2021, 3:04pm
bearcapital1 @bearcapital1
$XLRN I give this company no respect but prob the most consistent bio I follow in regards to execution. When I look… https://t.co/rfMCtz6bJ2
April 8th 2021, 12:04pm
MarcJacksonLA @MarcJacksonLA
$XLRN Acceleron Updates Phase 2 Sotatercept In Treating PAH Set For ATS 2021 https://t.co/pqh3LMfL49
April 7th 2021, 1:04pm
YuZhu4 @YuZhu4
RT @Quantumup1: Credit Suisse $XLRN blue sky valuation of $250 is based on (1) a 90% probability of success for luspatercept in myelofibro…
April 6th 2021, 6:04pm
maxm_profit @maxm_profit
RT @SeekingAlpha: $XLRN - Acceleron: Neutral On Stock Price Gains. https://t.co/rb9i7XfSVw #markets #business #stockmarket
April 6th 2021, 6:04pm
insidersanalyt1 @insidersanalyt1
on 2021-04-05 $XLRN insiders' SOLD 21864 securities equal to 0.0361% of outstanding shares. #finance #trading… https://t.co/h2BUGLxN5s
April 6th 2021, 6:04pm
Biotech2050 @Biotech2050
RT @semodough: JP $XLRN believe data continue to underscore the differentiated clinical potential of sotatercept for PAH, offering added mo…
April 6th 2021, 4:04pm
semodough @semodough
JP $XLRN believe data continue to underscore the differentiated clinical potential of sotatercept for PAH, offering… https://t.co/dQ0NChK4WX
April 6th 2021, 4:04pm
InsiderAlerts4U @InsiderAlerts4U
$XLRN: New Insider Filing on ACCELERON PHARMA INC's Director KAREN L. SMITH: https://t.co/MJasGOc7SM
April 6th 2021, 8:04am
newsfilterio @newsfilterio
$1,299,751.64 of shares sold by Smith Karen L. (Director), reported in a new form 4 filed with the SEC $XLRN https://t.co/b2KTbQIlth
April 6th 2021, 5:04am
newsfilterio @newsfilterio
$1,166,243.44 of shares sold by Zakrzewski Joseph S (Director), reported in a new form 4 filed with the SEC $XLRN https://t.co/07kcaOLqNh
April 6th 2021, 5:04am
newsfilterio @newsfilterio
Acceleron: Neutral On Stock Price Gains $XLRN https://t.co/rOFJ0gCnvc
April 6th 2021, 3:04am
Biotech2050 @Biotech2050
CS - $XLRN Updates from Sotatercept PULSAR and SPECTRA ATS Abstracts (Outperform PT raised to $151) #ATS21… https://t.co/WsA3suODLc
April 6th 2021, 3:04am
StckPro @StckPro
$XLRN NEW ARTICLE : Acceleron: Neutral On Stock Price Gains https://t.co/g2l3A8w87G Get all the latest $XLRN relate… https://t.co/ZHolChK45X
April 6th 2021, 1:04am
SeekingAlpha @SeekingAlpha
$XLRN - Acceleron: Neutral On Stock Price Gains. https://t.co/rb9i7XfSVw #markets #business #stockmarket
April 6th 2021, 1:04am
FlashAlert_me @FlashAlert_me
$XLRN [15s. delayed] filed SEC form 4: Director Zakrzewski Joseph S: Disposed 10,000 of Common Stock at average pr… https://t.co/cWwQ68R8p7
April 6th 2021, 12:04am
fintel_io @fintel_io
Insider Joseph S Zakrzewski reports selling 10,000 shares of $XLRN for a total cost of $1,407,343.44 https://t.co/Tq3qGBW5Z8
April 6th 2021, 12:04am
formwhisperscom @formwhisperscom
#FWSells $XLRN Smith Karen L., Director of ACCELERON PHARMA INC sold 11,864 shares on 2021-04-05. https://t.co/CXJ6yLgXfc
April 6th 2021, 12:04am
FlashAlert_me @FlashAlert_me
$XLRN [15s. delayed] filed SEC form 4: Director Smith Karen L.: Disposed 11,864 of Common Stock at average price $… https://t.co/vZuk1nAIOm
April 6th 2021, 12:04am
fintel_io @fintel_io
Insider Smith Karen L. reports selling 11,864 shares of $XLRN for a total cost of $1,663,156.14 https://t.co/b8rIFxMb7Z
April 6th 2021, 12:04am
Quantumup1 @Quantumup1
Credit Suisse $XLRN blue sky valuation of $250 is based on (1) a 90% probability of success for luspatercept in my… https://t.co/49GbwXWPg4
April 5th 2021, 10:04pm
MarcJacksonLA @MarcJacksonLA
$XLRN HC Wainwright Maintains Buy Rating On Acceleron Pharma, $168 PT https://t.co/Y7I3w8oVeE
April 5th 2021, 8:04pm
MarcJacksonLA @MarcJacksonLA
$XLRN Acceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hy… https://t.co/VxDV57YLrz
April 5th 2021, 2:04pm
Briefingcom @Briefingcom
$XLRN: Acceleron Pharma announced that updates from the PULSAR and SPECTRA Phase 2 clinical trials of sotatercept i… https://t.co/mD3zKs6ZRP
April 5th 2021, 1:04pm
Biotech2050 @Biotech2050
$XLRN abstracts https://t.co/e9tzjSnQsr
April 5th 2021, 12:04pm
PCCSMChiefs @PCCSMChiefs
RT @AcceleronPharma: $XLRN announces updates from the PULSAR and SPECTRA Ph. 2 clinical trials of an investigational agent in #PAH that wil…
April 5th 2021, 12:04pm
EdgarInsider @EdgarInsider
FORM 8-K [Press/News Current Report] recently SEC filed. $XLRN ACCELERON PHARMA INC https://t.co/xnO3NVckQz
April 5th 2021, 11:04am
fintel_io @fintel_io
$XLRN / Acceleron Pharma files form 8-K - Financial Statements and Exhibits - 8-K https://t.co/VfqOU0xVtG
April 5th 2021, 11:04am
AcceleronPharma @AcceleronPharma
$XLRN announces updates from the PULSAR and SPECTRA Ph. 2 clinical trials of an investigational agent in #PAH that… https://t.co/nf5SJSC0Aa
April 5th 2021, 11:04am
BIOTECH888 @BIOTECH888
RT @MSollender: $XLRN PULSAR and SPECTRA abstracts: https://t.co/FxFSe3h4ef https://t.co/lw1heObADp
April 5th 2021, 11:04am
MSollender @MSollender
$XLRN PULSAR and SPECTRA abstracts: https://t.co/FxFSe3h4ef https://t.co/lw1heObADp
April 5th 2021, 11:04am
stock_titan @stock_titan
$XLRN Acceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hy… https://t.co/vM3bNAJk6v
April 5th 2021, 11:04am
insiderbuyings @insiderbuyings
$XLRN new insider selling: 10000 shares. https://t.co/Ca3gOE5sTn
April 3rd 2021, 7:04am
formwhisperscom @formwhisperscom
#FWSells $XLRN Smith Karen L., Director of ACCELERON PHARMA INC sold 8,925 shares on 2021-04-01. https://t.co/CXJ6yLgXfc
April 3rd 2021, 3:04am
fintel_io @fintel_io
Insider Joseph S Zakrzewski reports selling 10,000 shares of $XLRN for a total cost of $1,346,382.36 https://t.co/Tq3qGBW5Z8
April 2nd 2021, 10:04pm
newsfilterio @newsfilterio
$1,105,282.36 of shares sold by Zakrzewski Joseph S (Director), reported in a new form 4 filed with the SEC $XLRN https://t.co/GVSFelKV5m
April 2nd 2021, 10:04pm
fintel_io @fintel_io
Insider Smith Karen L. reports selling 8,925 shares of $XLRN for a total cost of $1,218,002.72 https://t.co/b8rIFxMb7Z
April 2nd 2021, 10:04pm
newsfilterio @newsfilterio
$854,598.22 of shares sold by Smith Karen L. (Director), reported in a new form 4 filed with the SEC $XLRN https://t.co/YI7dZ5gW34
April 2nd 2021, 10:04pm
MarcJacksonLA @MarcJacksonLA
$XLRN New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with… https://t.co/8Q3IRKOKHC
April 1st 2021, 2:04pm
Briefingcom @Briefingcom
$XLRN: Acceleron Pharma announced the NEJM has published PULSAR Phase 2 trial results https://t.co/rzHbBvYwia
April 1st 2021, 1:04pm
StckPro @StckPro
$XLRN NEW ARTICLE : New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in… https://t.co/dOYBKvSOZB
April 1st 2021, 11:04am
sbwcws @sbwcws
Acceleron says NEJM publishes results of Pulsar Phase 2 trial of sotatercept $XLRN
April 1st 2021, 11:04am
FlashAlert_me @FlashAlert_me
$XLRN [15s. delayed]: Issued Press Release on April 01, 07:00:00: New England Journal of Medicine Publishes Results… https://t.co/NBLqbCwsI2
April 1st 2021, 11:04am
stock_titan @stock_titan
$XLRN New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with… https://t.co/ErE9EXCGZm
April 1st 2021, 11:04am

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2021. All rights reserved.